AlphAIAlphAI — Financial news for AI agents
onclive.comOCT 142 min read

FDA Receives NDA Resubmission for Rivoceranib Plus Camrelizumab in Frontline Unresectable or Metastatic HCC

Elevar Therapeutics resubmitted an NDA to the FDA for camrelizumab plus rivoceranib to treat unresectable or metastatic HCC. The submission follows a third CRL in July 2026, citing manufacturing issues. The NDA is supported by the CARES-310 trial, which showed improved overall and progression-free survival compared to sorafenib. Elevar's CEO expressed optimism about the FDA's review.

Original reporting
onclive.com
Published Oct 14, 2026, 6:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 7:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FDA Receives NDA Resubmission for Rivoceranib Plus Camrelizumab in Frontline Unresectable or Metastatic HCC — source image
Source · onclive.com
Decision brief

The 30-second read

Med
01

Why it matters

Approval would create a new competitor to sorafenib, potentially shifting market share in liver cancer treatments.

02

Market read

Regulatory outcome could affect biotech valuations and HCC therapy market dynamics.

03

What to watch

Manufacturing site issues and prior CRLs may signal deeper compliance challenges

Relevance 6/10Novelty 8/10Timing: upon FDA review

Background

Elevar Therapeutics seeks FDA approval for a first‑line HCC therapy after multiple complete response letters.

Market effects

Sector

Potential boost to biotech/oncology sector if approval granted

Regional

Limited to markets with exposure to Elevar's partners

Global

Modest, primarily affecting HCC treatment landscape

Counterpoint

What could challenge this read

Regulatory hurdles suggest possible further delays, limiting upside

Key entities

  • company
    Elevar Therapeutics

    Biopharma developing camrelizumab plus rivoceranib

  • company
    Hengrui Pharma

    Manufacturer of camrelizumab

Read at source← All news

Related articles

OCT 26
$ABBVMed

ESMO26: Novel combo successes signal shift from frontline chemo in cold cancers

At ESMO 2026, clinicians discussed novel cancer therapies like ADCs and bispecifics, highlighting their potential to replace chemotherapy in frontline treatments. AbbVie presented data on temab-A + Avastin, showing improved survival in colorectal cancer. ZaiLab's trial of zocilurtatug pelitecan + Tecentriq showed high response rates in small cell lung cancer without chemotherapy.

clinicaltrialsarena.com2 min
OCT 24
$AMGNHigh

DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC

Amgen's phase 3 trial (DeLLphi-305) showed that tarlatamab (Imdelltra) plus durvalumab (Imfinzi) improved overall survival (21.1 vs 12.7 months) and progression-free survival in extensive-stage small cell lung cancer (ES-SCLC) patients. The combination also increased objective response rates. Data were presented at the 2026 ESMO Congress and published in The New England Journal of Medicine. The trial enrolled 563 patients, with median follow-up of 15.9-16.1 months.

onclive.com3 min
OCT 23
$IOVAHigh

Iovance Biotherapeutics Reports 62.5% ORR and No-Reached Median OS in Final Phase 2 Analysis of Lifileucel Plus Pembrolizumab for Frontline Advanced Melanoma

Iovance Biotherapeutics (IOVA) reported final Phase 2 results for lifileucel plus pembrolizumab in frontline advanced melanoma, showing 62.5% ORR and 29.2% CR, with median OS not reached at 50.9 months. The data was presented at ESMO Congress 2026, supporting ongoing Phase 3 trial TILVANCE-301. The company estimates 70,000 addressable patients annually in global markets. Safety was consistent with known profiles.

quiverquant.com2 min